These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 30989171)

  • 1. A population pharmacokinetic study of benzathine benzylpenicillin G administration in children and adolescents with rheumatic heart disease: new insights for improved secondary prophylaxis strategies.
    Hand RM; Salman S; Newall N; Vine J; Page-Sharp M; Bowen AC; Gray K; Baker A; Kado J; Joseph J; Marsh J; Ramsay J; Sika-Paotonu D; Batty KT; Manning L; Carapetis J
    J Antimicrob Chemother; 2019 Jul; 74(7):1984-1991. PubMed ID: 30989171
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High risk of early sub-therapeutic penicillin concentrations after intramuscular benzathine penicillin G injections in Ethiopian children and adults with rheumatic heart disease.
    Ketema EB; Gishen NZ; Hailu A; Leul A; Hadgu A; Hagos K; Berhane S; Tsega T; Page-Sharp M; Davis TM; Moore B; Batty KT; Carapetis J; Salman S; Manning L
    PLoS Negl Trop Dis; 2021 Jun; 15(6):e0009399. PubMed ID: 34115748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Penicillin Dried Blood Spot Assay for Use in Patients Receiving Intramuscular Benzathine Penicillin G and Other Penicillin Preparations To Prevent Rheumatic Fever.
    Page-Sharp M; Coward J; Moore BR; Salman S; Marshall L; Davis TME; Batty KT; Manning L
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28559267
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population pharmacokinetic study of benzathine penicillin G administration in Indigenous children and young adults with rheumatic heart disease in the Northern Territory, Australia.
    Kado J; Salman S; Hand R; O'Brien M; Ralph A; Bowen AC; Page-Sharp M; Batty KT; Dolman V; Francis JR; Carapetis J; Manning L
    J Antimicrob Chemother; 2022 Sep; 77(10):2679-2682. PubMed ID: 35822635
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subcutaneous infusion of high-dose benzathine penicillin G is safe, tolerable, and suitable for less-frequent dosing for rheumatic heart disease secondary prophylaxis: a phase 1 open-label population pharmacokinetic study.
    Kado J; Salman S; Hla TK; Enkel S; Henderson R; Hand RM; Hort A; Page-Sharp M; Batty K; Moore BR; Bennett J; Anderson A; Carapetis J; Manning L
    Antimicrob Agents Chemother; 2023 Dec; 67(12):e0096223. PubMed ID: 37971244
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adherence to secondary prevention of rheumatic fever and rheumatic heart disease in young people: an 11-year retrospective study.
    Liaw J; Gorton S; Heal C; White A
    Aust N Z J Public Health; 2022 Dec; 46(6):758-763. PubMed ID: 35616403
    [TBL] [Abstract][Full Text] [Related]  

  • 7. "Hurts less, lasts longer"; a qualitative study on experiences of young people receiving high-dose subcutaneous injections of benzathine penicillin G to prevent rheumatic heart disease in New Zealand.
    Cooper J; Enkel SL; Moodley D; Dobinson H; Andersen E; Kado JH; Barr RK; Salman S; Baker MG; Carapetis JR; Manning L; Anderson A; Bennett J
    PLoS One; 2024; 19(5):e0302493. PubMed ID: 38743745
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improvement in rheumatic fever and rheumatic heart disease management and prevention using a health centre-based continuous quality improvement approach.
    Ralph AP; Fittock M; Schultz R; Thompson D; Dowden M; Clemens T; Parnaby MG; Clark M; McDonald MI; Edwards KN; Carapetis JR; Bailie RS
    BMC Health Serv Res; 2013 Dec; 13():525. PubMed ID: 24350582
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Penicillin concentrations after increased doses of benzathine penicillin G for prevention of secondary rheumatic fever.
    Currie BJ; Burt T; Kaplan EL
    Antimicrob Agents Chemother; 1994 May; 38(5):1203-4. PubMed ID: 8067767
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determining the impact of Benzathine penicillin G prophylaxis in children with latent rheumatic heart disease (GOAL trial): Study protocol for a randomized controlled trial.
    Beaton A; Okello E; Engelman D; Grobler A; Scheel A; DeWyer A; Sarnacki R; Omara IO; Rwebembera J; Sable C; Steer A
    Am Heart J; 2019 Sep; 215():95-105. PubMed ID: 31301533
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rheumatic fever prophylaxis using benzathine penicillin G (BPG): two- week versus four-week regimens: comparison of two brands of BPG.
    Kassem AS; Zaher SR; Abou Shleib H; el-Kholy AG; Madkour AA; Kaplan EL
    Pediatrics; 1996 Jun; 97(6 Pt 2):992-5. PubMed ID: 8637789
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intramuscular versus enteral penicillin prophylaxis to prevent progression of rheumatic heart disease: Study protocol for a noninferiority randomized trial (the GOALIE trial).
    Rwebembera J; Ndagire E; Carvalho N; Webel AR; Sable C; Okello E; Sarnacki R; Spaziani AM; Mucunguzi A; Engelman D; Grobler A; Steer A; Beaton A
    Am Heart J; 2024 Sep; 275():74-85. PubMed ID: 38797460
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subcutaneous administration of benzathine benzylpenicillin G has favourable pharmacokinetic characteristics for the prevention of rheumatic heart disease compared with intramuscular injection: a randomized, crossover, population pharmacokinetic study in healthy adult volunteers.
    Kado JH; Salman S; Henderson R; Hand R; Wyber R; Page-Sharp M; Batty K; Carapetis J; Manning L
    J Antimicrob Chemother; 2020 Oct; 75(10):2951-2959. PubMed ID: 32696033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Are the currently recommended doses of benzathine penicillin G adequate for secondary prophylaxis of rheumatic fever?
    Currie BJ
    Pediatrics; 1996 Jun; 97(6 Pt 2):989-91. PubMed ID: 8637788
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of a sustained release implant of benzathine penicillin G for secondary prophylaxis of rheumatic heart disease.
    Barr RK; Barber BW; Tait JR; Landersdorfer CB; Salman S; Musk GC; Page-Sharp M; Batty KT; Kado J; Manning L; Carapetis JR; Boyd BJ
    Eur J Pharm Biopharm; 2023 Aug; 189():240-250. PubMed ID: 37354997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A population pharmacokinetic modeling approach shows that serum penicillin G concentrations are below inhibitory concentrations by two weeks after benzathine penicillin G injection in the majority of young adults.
    Neely M; Kaplan EL; Blumer JL; Faix DJ; Broderick MP
    Antimicrob Agents Chemother; 2014 Nov; 58(11):6735-41. PubMed ID: 25182635
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Secondary prevention of rheumatic heart disease in Ethiopia: a multicenter study.
    Belay W; Dessie A; Ahmed H; Gedlu E; Mariyo A; Shehibo A; Tigabu Z; Aliyu MH; Soslow J
    BMC Cardiovasc Disord; 2022 Feb; 22(1):26. PubMed ID: 35109807
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sharing success - understanding barriers and enablers to secondary prophylaxis delivery for rheumatic fever and rheumatic heart disease.
    Chamberlain-Salaun J; Mills J; Kevat PM; Rémond MG; Maguire GP
    BMC Cardiovasc Disord; 2016 Aug; 16(1):166. PubMed ID: 27581750
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Qualitative assessment of healthy volunteer experience receiving subcutaneous infusions of high-dose benzathine penicillin G (SCIP) provides insights into design of late phase clinical studies.
    Enkel SL; Kado J; Hla TK; Salman S; Bennett J; Anderson A; Carapetis JR; Manning L
    PLoS One; 2023; 18(4):e0285037. PubMed ID: 37104500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Out-of-pocket expenditure for administration of benzathine penicillin G injections for secondary prophylaxis in patients with rheumatic heart disease: A registry-based data from a tertiary care center in Northern India.
    Arvind B; Saxena A; Kazi DS; Bolger AF
    Indian Heart J; 2021; 73(2):169-173. PubMed ID: 33865513
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.